

Carospir[®] (spironolactone) – First-time generic

- On November 2, 2023, [Amneal launched](#) an [AB-rated](#) generic version of CMP Pharma's [Carospir \(spironolactone\)](#) oral suspension.
 - In addition, Padagis launched an authorized brand alternative of Carospir.
- Carospir is approved:
 - For treatment of New York Heart Association Class III - IV heart failure and reduced ejection fraction in adult patients to increase survival, manage edema, and to reduce the need for hospitalization for heart failure
 - As an add-on therapy for the treatment of hypertension, to lower blood pressure in adult patients who are not adequately controlled on other agents, and
 - For the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restriction.
- Spironolactone is also available generically as a [tablet](#), and a combination [tablet with hydrochlorothiazide](#).
 - Spironolactone is indicated for the treatment of congestive heart failure (CHF), hypertension, edema associated with hepatic cirrhosis or nephrotic syndrome, and primary hyperaldosteronism.
 - Spironolactone and hydrochlorothiazide are indicated for edematous conditions associated with CHF, cirrhosis of the liver accompanied by edema and/or ascites, nephrotic syndrome, and essential hypertension.